Intercept Pharmaceuticals (BMV:ICPT *) - Aktienkurs, Nachrichten und Analyse

ICPT * Aktienübersicht

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Über das Unternehmen

ICPT * grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	4/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

36.7% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 63.85% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Die Aktionäre wurden im vergangenen Jahr verwässert

Intercept Pharmaceuticals, Inc. Wettbewerber

Genomma Lab Internacional. de

BMV:LAB B

Mex$15.9b

NatureCellLtd

KOSDAQ:A007390

₩630.7b

Cartesian Therapeutics

NasdaqGM:RNAC

US$407.4m

Kexing Biopharm

SHSE:688136

CN¥3.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Intercept Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$329.00
52-Wochen-Hoch	US$0
52-Wochen-Tief	US$0
Beta	1.27
11 Monat Veränderung	0%
3 Monate Veränderung	0%
1 Jahr Veränderung	0%
33 Jahre Veränderung	-83.98%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-78.86%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	ICPT *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	0%	0%	0%

Rendite im Vergleich zur Industrie: ICPT * übertraf die Branche MX Biotechs, die im vergangenen Jahr eine Rendite von 0.2 erzielte.

Rendite vs. Markt: ICPT * hinter dem Markt MX zurück, der im vergangenen Jahr eine Rendite von 1.2 erzielte.

Preisvolatilität

Is ICPT *'s price volatile compared to industry and market?
ICPT * volatility
ICPT * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiler Aktienkurs: ICPT * hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von ICPT * im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Intercept Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
ICPT * grundlegende Statistiken
Marktanteil	Mex$8.54b
Gewinn(TTM)	-Mex$3.00b
Umsatz(TTM)	Mex$5.09b

1.7x

Kurs-Umsatz-Verhältnis

-2.9x

Kurs-Gewinn-Verhältnis

Ist ICPT * zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ICPT * Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$294.52m
Kosten der Einnahmen	US$983.00k
Bruttogewinn	US$293.54m
Sonstige Ausgaben	US$466.84m
Umsatz	-US$173.30m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-4.16
Bruttomarge	99.67%
Nettogewinnspanne	-58.84%
Schulden/Eigenkapital-Verhältnis	495.7%

Wie hat sich ICPT * auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ICPT * Aktienübersicht

Belohnungen

Risikoanalyse

Intercept Pharmaceuticals, Inc. Wettbewerber

BMV:LAB B

Mex$15.9b

KOSDAQ:A007390

₩630.7b

NasdaqGM:RNAC

US$407.4m

SHSE:688136

CN¥3.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Recent updates

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Intercept Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

1.7x

-2.9x

Erträge &amp; Einnahmen

Erträge & Einnahmen